PHASE I CLINICAL TRIAL OF MURINE CD20 DNA VACCINATION IN DOGS WITH B-CELL LYMPHOMA

摘要

Lymphoma (LSA) is one of the most frequent tumors of dogs and the B-cell immunophenotype is the most common. While the majority of dogs with LSA respond to multi-agent chemotherapy protocols, resistance is common leading to median remission times of <1 year. Preclinical and clinical studies by our laboratory and others have shown that xenogeneic DNA vaccination can produce immune responses resulting in tumor rejection or protection and prolongation of survival. These studies provided the impetus formurine CD20 (muCD20) DNA vaccination in canine B-cell LSA.